Please assess the completion status of the following clinical trial:

Trial Title: IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient with metastatic renal clear cell (MRCC) adenocarcinoma, histologically proven by biopsy of the primary tumor and/or a metastasis. Prior nephrectomy is not required. The patient will be included in the study only if an efficacious cancer treatment can not be proposed.~* Patient to whom the currently available anticancer treatments are contra-indicated.~* Male or female 18 years or above. NB: Women must be either post-menopausal, rendered surgically sterile or practicing a reliable method of contraception (hormonal, intrauterine device or barrier). Pregnant women are excluded from this study.~* ECOG performance status 0-1.~* Expected survival longer than three months.~* Total white cell count ≥ 3.109/L.~* Platelet count ≥ 100.109/L.~* Hemoglobin \> 9 g/dL or \> 5.58 mmol/L.~* Serum creatinine \< 160 µmol/L.~* Total bilirubin \< 20 mmol/L, except for familial cholemia (Gilbert's disease)~* Serum ASAT and ALAT \< 3 times the upper limit of normal or \< 5 times upper limit of normal if liver metastases are present.~* Able to give written informed consent and to comply with the protocol.~Exclusion Criteria:~* Pregnancy, lactation or lack of effective contraception in fertile women of childbearing potential.~* Serious intercurrent infection within the 30 days prior to first administration.~* Known clinically active autoimmune disease.~* Known B or C active hepatitis.~* Known HIV positivity.~* Life threatening illness unrelated to cancer.~* Known cerebral metastases.~* Previous malignancies within the last two years other than successfully treated squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated with cone biopsy.~* Previous history of major psychiatric disorder requiring hospitalization or any current psychiatric disorder that would impede the patient's ability to provide informed consent or to comply with the protocol.~* Corticosteroids unless used as substitutive therapy.~* Past history of severe allergic episodes and/or Quincke edema.~* Past or present history of any organic disorder likely to modify absorption, distribution or elimination of the study drug.~* Alcohol or substance abuse disorder.~* IL-2 therapy or any other investigational agent within 30 days of first administration.~* Chemotherapy or radiotherapy within the past 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to first administration of the study drug or lack of recovery from adverse events (to grade 1 or less toxicity according to CTCAE 3.0) due to agents administered more than 4 weeks earlier. Exception is made regarding the x-ray treatment for painful bone metastases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).